Abstract
Recently, lifespan and healthspan have been extended in experimental animals using interventions that are potentially translatable into humans. A great deal of thought and work is needed beyond the usual steps in drug development to advance these findings into clinical application. Realistic pre-clinical and clinical trial paradigms need to be devised. Focusing on subjects with symptoms of age-related diseases or frailty or who are at imminent risk of developing these problems, measuring effects on short-term, clinically relevant outcomes, as opposed to long-term outcomes such as healthspan or lifespan, and developing biomarkers and outcome measures acceptable to regulatory agencies will be important. Research funding is a major roadblock, as is lack of investigators with combined expertise in the basic biology of aging, clinical geriatrics, and conducting investigational new drug clinical trials. Options are reviewed for developing a path from the bench to the bedside for interventions that target fundamental aging processes.
Original language | English (US) |
---|---|
Pages (from-to) | 1-5 |
Number of pages | 5 |
Journal | Experimental Gerontology |
Volume | 48 |
Issue number | 1 |
DOIs | |
State | Published - Jan 2013 |
Keywords
- Age-related disease
- Aging
- Cellular senescence
- Frailty
- Translation
ASJC Scopus subject areas
- Biochemistry
- Aging
- Molecular Biology
- Genetics
- Endocrinology
- Cell Biology